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Cerebral ischemia is a devastating disease that affects many people worldwide
every year. The neurodegenerative damage as a consequence of oxygen and energy
deprivation, to date, has no known effective treatment. The ischemic insult is followed by
an inflammatory response that involves a complex interaction between inflammatory cells
and molecules which play a role in the progression towards cell death. However, there is
presently a matter of controversy over whether inflammation could either be involved
in brain damage or be a necessary part of brain repair. The inflammatory response
is triggered by inflammasomes, key multiprotein complexes that promote secretion of
pro-inflammatory cytokines. An early event in post-ischemic brain tissue is the release of
certain molecules and reactive oxygen species (ROS) from injured neurons which induce
the expression of the nuclear factor-kappaB (NF-κB), a transcription factor involved in
the activation of the inflammasome. There are conflicting observations related to the role
of NF-κB. While some observe that NF-κB plays a damaging role, others suggest it to
be neuroprotective in the context of cerebral ischemia, indicating the need for additional
investigation. Here we discuss the dual role of the major inflammatory signaling pathways
and provide a review of the latest research aiming to clarify the relationship between NF-
κB mediated inflammation and neuronal death in cerebral ischemia.
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INTRODUCTION
Cerebral ischemia, due to insufficient blood supply to the brain, leads to neurodegeneration as a
consequence of deprivation of oxygen and energy needed for the metabolic requirements of the
brain. Ischemia can occur in two forms: focal ischemia (stroke), affecting a specific area of the brain
when a particular cerebral artery is occluded, or global ischemia, affecting the entire brain and
typically caused when cardiac activity comes to a halt, as in a cardiac arrest or during surgery (Zhang
et al., 2016).
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This devastating disease is one of the leading causes of death
as well as a major cause of adult disability from neurological
dysfunction (Katan and Luft, 2018; World Health Organization,
2018).
Lack of oxygen and glucose supply after cerebral ischemia
leads to neurons and glial cells being unable to maintain their
ionic homeostasis (Murphy, 2015). This triggers a complex
series of events known as the ischemic cascade, for review see
Iadecola and Anrather (2011) and Azad et al. (2016). Briefly,
the disruption of the cellular ionic gradients results in an excess
release of glutamate, causing an increase in the intracellular
calcium influx and excitotoxicity that initiates necrotic and
apoptotic cell death pathways. During these cell death processes,
reactive oxygen species (ROS) can be generated by cellular ionic
imbalances, which mediates membrane, mitochondrial, and
DNA damage resulting in protein misfolding and inflammation
(Iadecola and Anrather, 2011). Importantly, reperfusion after
cerebral ischemia also increases the production of ROS and the
inflammatory response, worsening neuronal injury (Wu et al.,
2018). All these processes seriously damage neurons, glia and
endothelial cells.
Despite major recent advances in the understanding of the
pathogenesis of cerebral ischemia, to date, there is no known
effective treatment. A large number of neuroprotective strategies
have shown disappointing results in clinical trials due to lack
of efficacy or undesirable side effects (Ginsberg, 2008). At
present, the most effective approach to reduce damage from
cerebral ischemia is the early restoration of cerebral blood flow
(Hankey, 2017). However, rapid revascularization after cerebral
ischemia can evoke secondary injury caused by the inflammatory
response. This cascade of events involves a complex interaction
between inflammatory cells and other molecules in the brain,
resulting in the release of inflammatory mediators which play
a role in the progression of cell damage and death (Shichita
et al., 2014; Khoshnam et al., 2017). The production of multiple
stimuli from injured ischemic neurons such as the influx of
calcium, the formation of ROS, and various other molecules
are early events in the postischemic brain that induce the
expression, among others, of the nuclear factor-kappaB (NF-κB),
a proinflammatory transcription factor involved in the activation
of the inflammasome (Shih et al., 2015) and a central player
in triggering the inflammatory response (Savage et al., 2012;
Baroja-Mazo et al., 2014; Gao et al., 2017). This review article
summarizes the major inflammatory signaling pathway and the
role of NF-κB in cerebral ischemia-induced-neuronal death.
THE INFLAMMATORY RESPONSE IN
CEREBRAL ISCHEMIA
How Does Inflammation Occur After
Cerebral Ischemia?
Inflammation is a crucial response of the innate immune system
that is activated by peripheral circulatory cells (Benakis et al.,
2014) and cerebral ischemia-induced neuronal damage to restore
homeostasis, tissue repair, and reorganization (Anrather and
Iadecola, 2016). However, chronic inflammatory response leads
to secondary injury after cerebral ischemia, which is why these
processes are so difficult to understand (Kawabori and Yenari,
2015; Banjara and Ghosh, 2017).
After cerebral artery occlusion, ROS production activates
endothelial cells with expression of adhesion molecules and
disruption of the blood-brain barrier (BBB; Abdullahi et al.,
2018; Bayraktutan, 2019) which allows infiltration of leukocytes
(Yang et al., 2019). Infiltrated leukocytes and microglia are
accumulated in the ischemic brain tissue releasing inflammatory
mediators. Infiltrated leukocytes such as neutrophils and
T lymphocytes produce pro-inflammatory cytokines and
cytotoxic substances, damaging cerebral tissue following
ischemia (Garcia-Bonilla et al., 2014; Strecker et al., 2017).
The activated microglia, the brain’s resident macrophages,
induce change in cell morphology to either pro-inflammatory
M1 or anti-inflammatory M2 phenotype (Lee et al., 2014).
In the ischemic brain, M1 microglia initiates post-ischemic
inflammation by generating interleukin (IL)-1β, ROS and
tumor necrosis factor (TNF) which further induces cytokine
and chemokine release from astrocytes and endothelial cells
(Anrather and Iadecola, 2016; Ma et al., 2017) which in turn,
exacerbate brain damage. In addition, M1 microglia also releases
matrix metalloproteinases (MMPs) which further enhance BBB
disruption (Shekhar et al., 2018). In contrast, M2 microglia
releases anti-inflammatory cytokines and growth factors which
mitigate ischemia-induced brain damage (Xiong et al., 2016;
Kanazawa et al., 2017; Figure 1A).
As an early postischemic event, the damage-associated
molecular patterns (DAMPs) are released. DAMPs are the
products of injured or stressed neurons and glial cells that
are originally intended to activate repair mechanisms (Patel,
2018). DAMPs include diverse types of molecules, such as
endogenous proteins, nucleic acids, and metabolites that trigger
an immune response leading to cell damage (Gadani et al.,
2015). Endogenous protein DAMPs, high mobility group
protein B1 (HMGB1; Deng et al., 2019), IL-33, IL-1α, Ca2 +
-binding S100 proteins (Bertheloot and Latz, 2017), heat
shock proteins (HSPs; Tamura et al., 2012), and peroxiredoxin
(PRXs; Nakamura and Shichita, 2019) are released after
cell damage and initiate inflammation. Another group of
DAMPs includes mitochondrial DNA (mtDNA; West and
Shadel, 2017), nucleotide derivatives such as ATP, uric acid,
and ROS (Heil and Land, 2014; Patel, 2018). DAMPs and
cytokines trigger activation of toll-like receptors (TLRs) which
are one of the several transmembrane pattern-recognition
receptors and play a pivotal role in the inflammatory response
after brain injury (Kumar, 2019). Activated TLRs increase
NLRP3 [nucleotide-binding oligomerization domain (NOD)-
like receptor protein 3] expression through the NF-κB signaling
pathway. Together with the adaptor ASC [apoptosis-associated
speck-like protein containing CARD (caspase recruitment
domain)] and procaspase-1, NLRP3 forms a caspase-1 activating
complex known as the NLRP3 inflammasome (Gao et al., 2017),
then the activated caspase-1 converts the pro-form to mature
form of pro-inflammatory cytokine IL-1 and IL-18 (Figure 1B).
We discuss the inflammation complex in more depth in the
‘‘Proinflammatory Role of Inflammasome’’ section.
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FIGURE 1 | Schematic overview of the postischemic inflammatory response and NF-κB signaling pathways mediating NLRP3 inflammasome activation. (A)
Cerebral ischemia triggers the disruption of the blood brain barrier (BBB) allowing for the macrophages to migrate to the ischemic area. Injured neurons release
DAMPs soon after the onset of ischemia, which can be detected by microglia, astrocytes, and macrophages initiating an inflammatory response. The inflammatory
molecules released by the glia have deleterious as well beneficial effects on neurons. M1 microglia generate interleukin (IL)-1β and tumor necrosis factor (TNF) which
further induce cytokine and chemokine release from astrocytes. M1 microglia also release MMPs, enhancing BBB disruption and worsening brain damage. A
beneficial role of glia consists of producing anti-inflammatory cytokines and trophic molecules. Additionally, astrocytes can be involved in the repair of the BBB. (B)
DAMPs and cytokines trigger TLR/cytokine receptor signaling, leading to NF-κB activation. NF-κB, a major factor in the inflammasome priming phase, is activated
upon phosphorylation of the inhibitor IκB by IKK. NF-κB can then translocate to the nucleus to induce transcription of the inflammasome complex elements. DAMPs
released by mitochondria (mtDAMPs) constitute the signal that triggers the assembly and activation of the inflammasome. Caspase-1 is activated by the
inflammasome and can transform the inactive pro-IL-1 into active IL-1 which can be released (see text for abbreviations).
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Proinflammatory Role of Inflammasome
Inflammasome is a multiprotein complex that mediates the
secretion of inflammatory cytokines by the immune system
and nerve cells, after perception of danger signals, triggering
cell death in cerebral ischemia (Gao et al., 2017; Mohamadi
et al., 2018). Among the different receptor proteins that can
form inflammasomes, NLRP3 is one of the best characterized
component of an NLR family (Wen et al., 2013; Broz and Dixit,
2016). NLRP3 inflammasome is formed by NACHT, a nucleotide
binding and oligomerization domain, a C-terminal leucine-rich
repeat (LRR), N-terminal adaptor protein ASC [that contains a
pyrin domain (PYD)] and procaspase-1 (Schroder and Tschopp,
2010; Voet et al., 2019; Feng et al., 2020).
Inflammasome complex activation and production of
cytokines are done by a well-regulated mechanism that requires
two phases. The priming phase involves activation of the
transmembrane TLRs by DAMPs from damaged and dead cells,
resulting in the upregulation of the NF-κB and MAPK signaling
pathways followed by the transcription of the inflammasome
protein and pro-IL-1β and pro-IL-18 (Bauernfeind et al.,
2011; Fann et al., 2013). The second phase is the activation of
the inflammasome complex by DAMPs, such mitochondrial
ROS, triggering oligomerization of the NLRP3 receptors and
recruitment of ASC (Rajanbabu et al., 2015). The ASC binds
to procaspase-1 resulting in its cleavage and conversion to
active caspase-1 that in turn triggers the activation of IL-1 and
IL-18 initiating inflammation (Schroder and Tschopp, 2010;
Sutterwala et al., 2014; Broz and Dixit, 2016; Gong et al., 2018).
NLRP3 inflammasome is expressed in microglia and neurons
(Song et al., 2017; Fann et al., 2018). The astrocytes secrete
pro-inflammatory cytokines, however, it has been reported that
NLRP3 inflammasome is not functional in mouse astrocytes
(Gustin et al., 2015). In contrast, Freeman et al. (2017) provided
direct evidence for the function of NLRP3 in astrocytes. Neuronal
and glial cell death after cerebral ischemia is correlated with
increased inflammasome activity (Fann et al., 2013; Ma et al.,
2019). Moreover, cerebral ischemia-induced neuronal cell death
and inflammasome expression are attenuated by NF-κB and
MAPK inhibitors (Fann et al., 2018; Figure 1B).
Anti-inflammatory Response by Glial Cells:
a Beneficial Effect of Inflammatory
Process
Cerebral ischemia induces cell death that activates the
inflammatory response, secretes pro-inflammatory cytokines,
and promotes further brain damage via activation of glial cells
(Iadecola and Anrather, 2011; Kawabori and Yenari, 2015;
Banjara and Ghosh, 2017). However, depending on the context
and timing, activated glial cells also play a beneficial role by
removing dead cells and promoting recovery (Jayaraj et al., 2019;
Sakai and Shichita, 2019). Resolution of inflammation and tissue
repair is a contribution of activated M2 microglia which become
phagocytic and clear tissue damage (Iadecola andAnrather, 2011;
Zhang, 2019). They also release anti-inflammatory cytokines
such as TGF-β, IL-4, IL-10, IL-13, growth factors, progranulin
which represses inflammation and alleviates brain damage after
ischemic insults (Xiong et al., 2016; Kanazawa et al., 2017) and
produce insulin-like growth factor (IGF)-1 during the reparative
phase of the inflammation (Amantea et al., 2014). Moreover,
brain injury after cerebral ischemia is exacerbated by the deletion
of proliferating microglia (Lalancette-Hébert et al., 2007) and is
attenuated by administration of exogenous microglia (Imai et al.,
2007).
Astroglia also play a beneficial role in the process of
inflammation. Several studies suggest that the astrocytes
reactions are involved in the repair and neuroprotection by
reconstructing the BBB (del Zoppo, 2009) and delivering
neurotrophic factors (Shen et al., 2010) in cerebral ischemia.
Ischemia activates astrocytes and increases glial fibrillary acidic
protein (GFAP) expression, reactive gliosis, and glial scar with
both detrimental and beneficial functions (Liu and Chopp,
2016; Pekny et al., 2019). Astrocytes form functional borders
that regulate the inflammatory cells, restraining the extent
of neurotoxic inflammation (Sofroniew, 2015). The deletion
of reactive astrocytes has been shown to frustrate the BBB
repair, increasing inflammation and tissue damage after cerebral
ischemia (Li et al., 2008). On the other hand, induction
of astrocyte proliferation is correlated with neuroprotection
in cerebral ischemia models (Keiner et al., 2008). These
studies indicate that inflammatory cells in the CNS have a
dual role, both beneficial and deleterious by activating and
repressing inflammation in a time- and context-dependent
manner (Figure 1A).
NF-κB IN THE BRAIN
The pleiotropic transcription factor NF-κB, as a key regulator
of numerous cellular signaling pathways, is involved in cell
survival, immune responses, and inflammation (Shih et al., 2015).
NF-κB contains dimers of the Rel protein family that includes
RelA (p65), p50, p52, Rel B, and C-Rel. It is amply expressed
in neurons and glial cells as a heterodimer of RelA (p65) and
p50 subunits (Ridder and Schwaninger, 2009). Under resting
conditions, NF-κB dimers are retained in the cytoplasm, in an
inactive state, by interacting with its endogenous inhibitor IκB to
prevent nuclear translocation (Napetschnig and Wu, 2013).
Two major signaling pathways can activate NF-κB, canonical
and noncanonical pathways. The most researched canonical
NF-κB pathway is activated by many different exogenous and
endogenous factors, including DAMPs, cytokines, ROS, growth
factors, immune-related receptors, and other signals such as
neurotransmitters and nerve growth factors. These factors are
perceived by specific membrane receptors such as TLRs and IL-1
receptors and many others that trigger the activation of the IKK
(IκB upstream kinase). IKK activation induces phosphorylation,
ubiquitination, and degradation of the IκB resulting in NF-κB
translocation to the nucleus and stimulation of the transcription
of many different genes (Ridder and Schwaninger, 2009). The
noncanonical NF-κB pathway responds to ligands of members of
the TNF family receptor and does not rely on IκB degradation
but rather depends on the processing of the NF-κB precursor
(Sun, 2012). Canonical NF-κB pathway is involved in both acute
and chronic inflammatory responses and in cell survival whereas
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noncanonical NF-κB pathway cooperates with canonical NF-κB
pathway in regulating different immune functions (Sun, 2017).
NF-κB is highly expressed in all cell types in the brain with
different functions. NF-κB is observed in neuronal processes and
in isolated synapses (Meffert et al., 2003). It is constitutively
activated in hippocampal neurons (Fridmacher et al., 2003),
in GABAergic interneurons (O’Mahony et al., 2006) as well
as in other types of neurons from various regions of the
brain (Shih et al., 2015). Many different stimuli have been
shown to activate neuronal NF-κB including inflammatory
mediators, neuronal growth factor (NGF), brain-derived growth
factor (BDNF), and excitatory neurotransmitters (Snow and
Albensi, 2016). Neuronal NF-κB is activated through NMDA
glutamate receptors and L-type voltage calcium channels in
neurons from the hippocampus, cerebellum, and the cortex
(Meffert and Baltimore, 2005). Under physiological conditions,
NF-κB promotes synaptic activity which maintains the ideal
basal constitutive level in neurons and is repressed by IκB in an
autoregulatory manner (Dresselhaus andMeffert, 2019). Trophic
factor deprivation decreases NF-κB activity in cerebellar neurons
by increasing the NF-κB inhibitor IκB (Kovács et al., 2004).
NF-κB signaling disruption increases neurodegeneration in
excitatory neurons (Fridmacher et al., 2003) and in GABAergic
interneurons indicating a role for NF-κB in synaptic plasticity
and memory (O’Mahony et al., 2006). On the other hand, NF-κB
activation promotes dendritic spines while the inhibition of NF-
κB activity reduces dendritic spines suggesting a role for NF-κB
in the excitatory synaptic function (Boersma et al., 2011). NF-κB
regulates a large number of gene targets implicated in neuronal
synaptic plasticity that are involved in behavior (Dresselhaus and
Meffert, 2019). Additionally, several studies cite evidence that the
activation of NF-κB is required for neuronal survival (Bhakar
et al., 2002; Kaltschmidt et al., 2005; Mattson and Meffert, 2006).
In contrast, NF-κB has low basal activity in glial cells and
there is no report indicating that glial NF-κB can be activated
under resting state or by neurotransmitters as in the case with
neurons. However, it has been reported that microglial NF-κB
appears to have a role in the development and regulation of
neuronal excitability and synaptic plasticity (Kyrargyri et al.,
2015). Astrocytes have an important function in forming the BBB
as well as in neuronal support and repair. Moreover, astrocytes
are involved in the termination of excitatory signals by removing
glutamate from synapses that rely on NF-κB activation (Ghosh
et al., 2011).
ROLE OF NF-κB IN CEREBRAL ISCHEMIA
The main controversy is whether NF-κB activation has a
neuroprotective role or its function as an inflammatory mediator
exacerbates neuronal damage after cerebral ischemia. NF-
κB regulates caspase inhibitors, TNF-receptor associate factor
(TRAF), and the Bcl-2 family proteins (Wang et al., 1998,
1999) increasing cell survival. These antiapoptotic and survival-
promoting genes can code for resistance to cell death under
pathological conditions (Yang et al., 2007; Mettang et al., 2018).
Overexpression of p65 rescued apoptotic cortical neurons while
selective inhibition of NF-κB enhanced damage (Bhakar et al.,
2002) suggests that NF-κB is involved in an anti-apoptotic
function in neurons. In contrast, other studies propose that the
neuronal activation of NF-κB contributes to the death of neurons
after cerebral ischemia (Nurmi et al., 2004; Zhang et al., 2005).
NF-κB is activated in degenerating hippocampal CA1 neurons
24–72 h after global ischemia (Clemens et al., 1997) and 24 h after
focal ischemia in association with reactive glial cells, and at later
times, in rats (Gabriel et al., 1999). Moreover, infarct volumes are
decreased in experiments with mice lacking the p50 subunit of
NF-κB indicating that NF-κB activation could promote neuronal
death after ischemia (Nurmi et al., 2004). NF-κB has different
functions that may depend on the NF-κB complex composition
(Lanzillotta et al., 2015).
Besides neurons, NF-κB signaling pathways in glia can be
activated in response to injury through TLR signaling, increasing
the production of inflammatory mediators (Dresselhaus and
Meffert, 2019). Microglia, the immune resident macrophages
in the brain, can become activated by an NF-κB-mediated
mechanism under injury conditions. This activation can
trigger a release of large amounts of pro-inflammatory
cytokines, such as TNFα, IL-1β, and ROS (Block et al.,
2007) that can generate secondary neurotoxicity aggravating
neurodegeneration. Astrocyte activation by TLR is involved in
innate immune reactions secreting IL-1β and IL-6 (Kopitar-
Jerala, 2015) and after cerebral ischemia, astrocytes are involved
in inflammation mediated by NF-κB (Deng et al., 2018).
Astroglial NF-κB inhibition induces a decrease in the expression
of chemokines and leukocyte infiltration showing a role in the
intracellular pro-inflammatory activation (Gonzalez-Reyes and
Rubiano, 2018).
Neurotoxicity mediated by glial cells may give an
explanation of the neuronal damage and NF-κB activity
decreases after cerebral ischemia (Mattson and Meffert, 2006).
Considerable evidence now suggests that neuronal NF-κB has
an anti-apoptotic and survival role while its activation in glial
cells is involved in inflammation and cell death. NF-κB’s possible
protective role in neurons should be separated from the most
likely probable degenerative role in glia (Kaltschmidt et al., 2005;
Dresselhaus and Meffert, 2019).
CONCLUSIONS
Inflammation is a central component in the progression of cell
damage after cerebral ischemia that involves neurons, glia, and
immune cells. Growing evidence indicates that inflammation
has a dual role: while the acute inflammatory response seems
to aggravate an ischemic injury, the recovery and tissue repair
depend on later inflammatory processes. Moreover, it is accepted
that pro-inflammatory glial and immune cells in the acute phase
of ischemia may differentiate into anti-inflammatory cells that
contribute to the regeneration processes during the chronic
phase of cerebral ischemia. It is well established that NF-
κB has a crucial role in cell survival and inflammation. All
brain cell types express NF-κB, but under basal conditions it
is constitutively activated in neurons, while it has little activity
in glial cells, showing different functions in different nerve
cells. Neuronal NF-κB has a potential preservative role that
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should be differentiated from the degenerative role it plays in
glial cells under ischemic conditions. Based on all the above,
an ideal and successful anti-inflammatory treatment should
attack and inhibit, in a very selective manner, the deleterious
constituents of the inflammatory process during cerebral
ischemia and, simultaneously, enhance the beneficial aspects of
the inflammatory response. Additionally, the treatment should
selectively target, in its actions, different cell types. In the context
of cerebral ischemia, a deeper understanding of the step-by-step
progression of the inflammatory cascade as well as the specific
functions of NF-κB, in the different cell types, is crucial for the
development of an effective therapeutic regimen.
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